Bulletin
Investor Alert

Jan. 11, 2021, 9:38 a.m. EST

Biden plans to distribute COVID-19 vaccine doses immediately

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    BioNTech SE ADR (BNTX)
  • X
    Pfizer Inc. (PFE)
  • X
    Moderna Inc. (MRNA)

or Cancel Already have a watchlist? Log In

Jaimy Lee

President-elect Joe Biden plans to distribute available doses of COVID-19 vaccines when he comes into office on Jan. 20, in the latest proposal made by government officials in the U.S. and abroad as they work to speed up a slow and complicated vaccination rollout.

“He supports releasing available doses immediately and believes the government should stop holding back vaccine supply so we can get more shots in Americans’ arms now,” T.J. Ducklo, a spokesperson for Biden’s transition team, said in an email. 

The Department of Health and Human Services had reportedly only distributed 45% of available vaccines in the U.S., as of Christmas Eve, according to a Dec. 24 op-ed written by a conservative columnist for The Washington Post.

Governors of eight states including California, Kansas, and New York sent a letter Friday to the government citing the op-ed and demanding “the federal government begin distributing these reserved doses to states immediately.”

See also: Pfizer–BioNTech vaccine appears to protect against U.K. and South African COVID-19 strains in lab, study finds

There are currently two COVID-19 vaccines available in the U.S.: BioNTech SE /zigman2/quotes/214419716/composite BNTX +7.69% and Pfizer Inc.’s /zigman2/quotes/202877789/composite PFE +2.58% BNT162b2 and Moderna Inc.’s /zigman2/quotes/205619834/composite MRNA +6.84% mRNA-1273. The vaccines, both of which are mRNA vaccines, require two doses, spaced a few weeks apart. (For BioNTech/Pfizer’s vaccine, that’s 21 days; for Moderna’s vaccine, it’s 28 days.)

In the month or so since both vaccines received emergency authorization from the Food and Drug Administration, the U.S. has missed its targets for vaccination. The Trump administration had called for 20 million people to be vaccinated in December, down from an original target of 100 million. As of Jan. 7, about 6 million people in the U.S., have received at least one dose of either vaccine, according to the Centers for Disease Control and Prevention

In recent weeks, a series of new proposals in the European Union, the U.S., and the U.K. aim to change the dosing schedules of two-dose vaccines in a bid to speed up immunization. The suggestions come at a time when coronavirus case counts, hospitalizations, and deaths are surging. The U.S. on Thursday recorded more than 4,000 deaths in a single day from COVID-19.

But not all regulators are on board. The FDA has raised concerns about altering dosing schedules that were established during the closely watched clinical-trial process for both mRNA vaccines. 

Read: Slaoui proposes half-doses of Moderna’s COVID-19 vaccine to speed vaccinations

In a statement on Monday, FDA commissioner Dr. Stephen Hahn acknowledged that proposals to change dosing regimens to hasten immunizations are “reasonable” questions.

“We know that some of these discussions about changing the dosing schedule or dose are based on a belief that changing the dose or dosing schedule can help get more vaccine to the public faster,” he said. “However, making such changes that are not supported by adequate scientific evidence may ultimately be counterproductive to public health.”

Pfizer has also expressed concern about proposed changes to dosing.

“Pfizer believes it is critical health authorities conduct surveillance efforts on any alternative schedules implemented and to ensure each recipient is afforded the maximum possible protection, which means immunization with two doses of the vaccine,” a spokesperson for the company told MarketWatch in December.

/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 151.54
+10.82 +7.69%
Volume: 4.62M
April 16, 2021 4:00p
P/E Ratio
1,446
Dividend Yield
N/A
Market Cap
$33.99 billion
Rev. per Employee
$283,276
loading...
/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 38.57
+0.97 +2.58%
Volume: 52.83M
April 16, 2021 4:02p
P/E Ratio
22.56
Dividend Yield
4.04%
Market Cap
$209.74 billion
Rev. per Employee
$533,860
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 170.81
+10.94 +6.84%
Volume: 19.04M
April 16, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$63.98 billion
Rev. per Employee
$617,996
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.